BioNTech SE (22UA) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.023x

Based on the latest financial reports, BioNTech SE (22UA) has a cash flow conversion efficiency ratio of -0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-421.00 Million ≈ $-492.19 Million USD) by net assets (€18.70 Billion ≈ $21.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioNTech SE liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

BioNTech SE - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BioNTech SE Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
International Flavors & Fragrances Inc NYSE:IFF	0.022x
Amer Sports, Inc. NYSE:AS	0.107x
China Merchants Securities Co Ltd SHG:600999	-0.097x
China United Network Communications Ltd SHG:600050	0.077x
Merck KGaA XETRA:MRK	0.045x
Incyte Corporation NASDAQ:INCY	0.067x
Brown & Brown Inc NYSE:BRO	0.021x
Snap-On Inc NYSE:SNA	0.045x

Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2025)

The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see BioNTech SE (22UA) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€19.22 Billion ≈ $22.48 Billion	€456.00 Million ≈ $533.11 Million	0.024x	+121.68%
2024-12-31	€19.41 Billion ≈ $22.69 Billion	€207.70 Million ≈ $242.82 Million	0.011x	-95.97%
2023-12-31	€20.25 Billion ≈ $23.67 Billion	€5.37 Billion ≈ $6.28 Billion	0.265x	-60.81%
2022-12-31	€20.06 Billion ≈ $23.45 Billion	€13.58 Billion ≈ $15.87 Billion	0.677x	+805.01%
2021-12-31	€11.89 Billion ≈ $13.90 Billion	€889.70 Million ≈ $1.04 Billion	0.075x	+860.15%
2020-12-31	€1.37 Billion ≈ $1.60 Billion	€-13.50 Million ≈ $-15.78 Million	-0.010x	+97.55%
2019-12-31	€493.49 Million ≈ $576.94 Million	€-198.50 Million ≈ $-232.07 Million	-0.402x	-82.41%
2018-12-31	€267.00 Million ≈ $312.15 Million	€-58.88 Million ≈ $-68.83 Million	-0.221x	-120.22%
2017-12-31	€-48.21 Million ≈ $-56.36 Million	€-52.56 Million ≈ $-61.45 Million	1.090x	--

About BioNTech SE

F:22UA Germany Biotechnology

Market Cap

$23.08 Billion

€19.74 Billion EUR

Market Cap Rank

#1304 Global

#286 in Germany

Share Price

€78.05

Change (1 day)

+0.39%

52-Week Range

€72.05 - €102.20

All Time High

€377.00